anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a Chinese herbal medicine for treating haemorrhoids. The Chinese herbal medicine consists of the following components in parts by weight: 35 parts of garden burnet root, 25 parts of sophora flower, 25 parts of honeysuckle flower, 35 parts of glabrous greenbrier rhizome, 35 parts of baikal skullcap root, 25 parts of fried bitter orange, 35 parts of Chinese angelica, 30 parts of divaricate saposhnikovia root, 20 parts of Chinese gall, 25 parts of Japanese ampelopsis root, 40 parts of black bean and 40 parts of black fungus. The Chinese herbal medicine is prepared by carrying out the following steps: adding 1500 parts of water; boiling, and decocting with soft fire for 20-30 minutes; collecting supernatant by filtering; decocting for three times, and mixing supernatant decocted in the three times; bottling, and sterilizing at high temperature for later use. The garden burnet root is taken as a monarch; the sophora flower and the honeysuckle flower are taken as ministers; the glabrous greenbrier rhizome, the baikal skullcap root and the fried bitter orange are taken as assistants; the Chinese angelica, the divaricate saposhnikovia root, the Chinese gall, the Japanese ampelopsis root, the black bean and the black fungus are taken as guides. The Chinese herbal medicine composition for treating haemorrhoids can be used for effectively treating haemorrhoids. As proved by practice examination, the Chinese herbal medicine composition is safe and free from side effects, is very remarkable in treatment effect, convenient to take and low in treatment cost, and has the effect of treating both symptoms and root causes.
Subjects with mild asthma will be treated with placebo medication for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. The placebo mediation will consist of the same diluent used for suspending the omalizumab without omalizumab added.
Testosterone has complex effects on psychological traits and behavior; it is associated with social dominance and competition and is a potential human sex pheromone. This study aimed to investigate the associations between testosterone levels, aggressive behavior, and manic symptoms using a network analysis among bipolar disorder (BD) patients in psychiatric emergency departments (PED). Data from January 2021 and March 2022 BD patients in PED were analyzed. Manic symptoms were assessed using the Young Mania Rating Scale (YMRS). Aggression was assessed with subscale of the PANSS scale (PANSS-AG). The undirected network structures of testosterone levels, aggressive behavior, and manic symptoms were estimated, and centrality and bridge centrality indices were examined. Network stability was examined using the case-dropping procedure. The Network Comparison Test (NCT) was conducted to evaluate whether network characteristics differed by gender. We recruited a total of 898 BD patients, with the mean YMRS score as 13.30 ± 9.58. The prevalence of level II aggression was 35.6% (95%CI = 32.5%-38.7%), level III aggression was 29.5% (95%CI = 26.3%-32.6%), and level VI aggression was 7.0% (95%CI = 5.4%-8.8%). The male participants had a mean testosterone level of 391.71 (Standard Deviation (SD):223.39) compared to 36.90 (SD:30.50) for female participants in the whole sample. Through network analysis, "Increased motor activity-energy" emerged as the central symptom, with the highest centrality expected influence, followed by "Emotional Instability" and "Disruptive/aggression behavior". Notably, "Emotional Instability" appeared to be the bridge symptom linking manic symptoms to aggressive behavior. Within the flow network model, "Speech rate and amount" exhibited the strongest positive correlation with testosterone levels, followed closely by "Disruptive/aggression behavior". The constructed network model demonstrated robust stability, with gender showing no significant impact on the structure. In this study, "Increased motor activity-energy" stood out as the most influential symptom, and "Speech rate and amount" acted as the main bridge symptom linking testosterone levels, aggressive behavior, and manic symptoms. Targeting the central and bridge symptoms may improve the outcomes of aggression interventions implemented among BD patients in psychiatric emergency care.
The invention relates to a drug for treating neurasthenia. The drug is prepared from, by weight, 9 parts of all-grass of circaea quadrisulcata, 12 parts of cortex albiziae, 5 parts of herba siegesbeckiae, 5 parts of rhizoma acori graminei, 8 parts of herba ecliptae, 11 parts of fructus rosae laevigatae, 9 parts of semen cuscutae and 6 parts of dutchmanspipe root. Circaea quadrisulcata can regulate qi to alleviate pain, promote urination and relieve internal heat or fever, and promote blood circulation to restore menstrual flow. Cortex albiziae can sooth the nerve and relieve depression, and activate blood and expel carbuncle. Herba siegesbeckiae can dispel wind and remove phlegm, dredge collaterals and stop spasm, and relieve dampness and relieve internal heat or fever. Rhizoma acori graminei can dissipate phlegm for resuscitation, resolve dampness and promote the circulation of qi, dispel wind and relieve pain or numbness, and relieve swelling and pain. Herba ecliptae can tonify the liver and kidney, cool blood and achieve hemostasis. Fructus rosae laevigatae can secure essence and reduce urination and astringe intestine to check vaginal discharge. Semen cuscutae can tonify kidney and boost essence, nourish the liver to improve visual acuity, secure the fetus and stop diarrhea. Dutchmanspipe root can promote qi circulation to relieve pain, achieve detumescence by detoxification, and calm liver to reduce blood pressure. Through the combination of the medicinal materials, the functions of promoting qi circulation and relieving depression, clearing liver fire, tonifying qi and nourishing heart, and soothing the nerve and stabilizing the mind are realized. Clinical experiments prove that drug can effectively treat neurasthenia.
What is disclosed is a system and method for forecasting and imputing an unknown vital measurement of a patient. Temporally successive patient vital measurements are received which comprise irregularly sampled observations {y 1 , . . . , y N }, where y j  denotes the j th  observation at time t j , and N is the number of samples. The vital measurements are then provided to a model trained using historical data of patient vital measurements. The model generates a parameter set θ=(A,B,C), where A is a state transition matrix, B is a control matrix, and C is a matrix which maps state-space variables to observation variables. The parameters are used to obtain state-space variable z t  which, in turn, is used to forecast an unknown observation y N+1  or to impute an unknown observation y t , where 1<t<N. The historical data is then updated with the forecasted observation y N+1  or the imputed unknown observation y t .
A radiation applicator comprises a plastic carrier material having distributed therein a radioactive substance which does not emit gaseous decomposition products, the applicator being under the conditions of use at body temperature, mouldable, coherent and self sustaining in any form to which it is moulded.  The preferred radioactive substance is cobalt isotope 60, preferably in the form of the oxide, or other synthetic beta and/or gamma emitters.  Plastic materials referred to are rubber, chicle gum, paraffin wax and synthetic thermoplastic materials including organic silicon compounds.  The applicator is preferably transparent.ALSO:A radiation applicator comprises a plastic carrier material having distributed therein a radioactive substance which does not emit gaseous decomposition products, the applicator being under the conditions of use at body temperatures, mouldable, coherent and self-sustaining in any form to which it is moulded.  The preferred radioactive substance is cobalt isotope 60, preferably in the form of the oxide, or other synthetic beta and/or gamma emitters.  Plastic materials referred to are rubber, chide gum, paraffin wax, and synthetic thermoplastic materials including organic silicon compounds.  The applicator is preferably transparent.
Classical chemoradiotherapy will be conducted by clinical routine method. Radiation will be given by external beam of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks. Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime and for patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug. Hydrochloride anlotinib will be orally taken daily at a dose level of 12mg for 14 days. Then rest for 7 days and start a new cycles for a total of 3 cycles. First capsule of anlotinib will be taken 7 days before the first radiation.
The greatest challenge in cancer is relapsed disease. Despite best available therapies, approximately 20% of acute myeloid leukemia (AML) patients and 80% of myelodysplastic syndrome (MDS) patients die of relapsed disease. Minimal residual disease (MRD) is the main predictor of refractory disease following chemotherapy. In AML and MDS patients, mutant allele frequency (MAF) associates with future occurrence of relapse. Current oncology practice relies on painful bone marrow biopsies and light microscopy to monitor disease progression, remission, and relapse. Because of the bias in disease sampling and low sensitivity testing, there is an urgent need for a higher sensitivity test to monitor the tumor burden in these patients. The Investigator developed a rapid and ultrahigh sensitivity method to detect cancer-associated mutant alleles. This study will use our droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma MAF in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR. Results from this project will generate a non-invasive means to monitor cancer response and progression months before current clinical methods, and provide an opportunity to intervene before the patient relapses. Furthermore, establishing a quantitative method to measure cancer burden will empower clinical researchers to measure biological activity in phase II and III clinical trials of new therapeutic agents.
Study Phase and Design Phase I with experimental malaria challenge. The study will enroll 30 healthy adult participants randomized to one of three cohorts comprised of six groups of 5 individuals per group to simultaneously receive PfSPZ Challenge via the ID route. The goal will be to determine the optimal dose required to achieve 100% infectivity (ID100) of adult volunteers. The parameters of 1) dose (number of sporozoites) 2) number of injections and 3) aliquot volume will be studied; adding to previous data collected at the University of Nijmegen. The following single time point inoculation regimens (a-f) will be assessed: Cohort 1: Medium dose, medium aliquot volume: a. 10,000 PfSPZ ID in 2 divided doses of 50 microliter aliquot volume b. 10,000 PfSPZ ID in 8 divided doses of 50 microliter aliquot volume Cohort 2: Medium dose, low aliquot volume: c. 10,000 PfSPZ ID in 2 divided doses of 10 microliter aliquot volume d. 10,000 PfSPZ ID in 8 divided doses of 10 ml aliquot volume Cohort 3: High dose, low aliquot volume: e. 50,000 PfSPZ ID in 2 divided doses of 10 ml aliquot volume f. 50,000 PfSPZ ID in 8 divided doses of 10 ml aliquot volume. Safety, tolerability and efficacy of the inoculation regimens will be evaluated. All 30 volunteers will be evaluated as part of an inpatient stay (Days 8-18 post-injection) to diagnose and treat Pf malaria infection with chloroquine. Following review, and with the assistance of an independent SMC, 2 regimens will be chosen for further testing in DMID 11-0042. The following criteria strategy will be employed in the order listed: 1. Regimen necessary to achieve ID100 of adult volunteers; 2. Regimen eliciting Pf patency and parasite density (as detected by qRT-PCR) that most closely approximates patency rates experienced after mosquito challenge; 3. Regimen requiring the least number of injections; 4. Regimen utilizing the fewest number of PfSPZ; 5. Volume of administration considered to be the easiest to administer by the clinicians. Chloroquine sub-study: Eighteen of thirty participants (3 volunteers from each of the six groups comprised of 5-subjects/group) will be assigned to participate in a CQ and possibly desethylchloroquine blood and urine study designed to assess the drug kinetics of CQ over the course of four weeks after standard CQ dose administration.
Participants received treatment with bosentan 125 milligrams (mg) twice daily and sildenafil thrice daily for 8 days in treatment period 1. Participants were on the same sildenafil dose level (20, 40, 50 or 60 mg) they had been at study entry which was well tolerated in conjunction with bosentan. Following treatment period 1, the participants received concomitant treatment of oral imatinib 200 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 2. Following treatment period 2, the participants received concomitant treatment of oral imatinib 400 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 3.
PURPOSE:To provide the subject composition consisting of a mixture of interleukins having 3 kinds of N-terminal amino acid sequences, simultaneously produced from human fibroblast by a super induction method for the production of human IFN-beta and separated and purified from the product. CONSTITUTION:The objective natural-type human interleukin 6 composition contains 3 kinds of human interleukin 6 (IL-6) originated from human fibroblast and having the N-terminal amino acid sequences of formula I, formula II and formula m at ratios of 3:5:2. A cultured liquid of fibroblast produced by super-induction method is treated with an insoluble carrier bonded with a blue dye to adsorb the most part of IFN-beta and obtain a non-specific adsorbed fraction containing >=90% of IL-6. Said fraction is made to contact with a silica adsorbent to effect the adsorption of IL-6 and eluted with an acidic solution. The obtained solution is subjected to salting-out to precipitate IFN-beta and other contaminant proteins and obtain a supernatant containing IL-6. The objective purified composition is produced by hydrophobic chromatographic treatment of the supernatant.
FIELD: medicine. SUBSTANCE: method involves applying complex therapy. Instenon is administered in addition depending on disease form. Severe generalized and ascending forms of diphtheric polyneuropathy and polyradiculoneuritis are administered at the beginning of the disease in intravenous dripping mode at a dose of 1 to 2.0 ml once a day depending on patient age during 5-10 days. Then the preparations are administered per os at a dose of 1/3 to 1 dragee 3 times a day depending on the degree the neurologic symptoms are marked. Facial nerve neuritis, or poliomyelitis and diphtheric polyneuropathy and polyradiculoneuritis of moderate severity degree being the case, Instenon is intramuscularly administered at a dose of 1 to 2.0 ml once a day during 5-10 days in acute period. Its following peroral administration during restitution and convalescence period is applied during 2-6 weeks. Poliomyelitis-like diseases and light cases of facial nerve neuritis, diphtheric polyneuropathy and polyradiculoneuritis being the case, Instenon is per os administered during 2-4 weeks in the first days of the disease in combination with Instenon electrophoresis on the area of injured segments. Its following administration as applications in convalescence period is prescribed when some residual phenomena are available. EFFECT: accelerated treatment course.
Delefilcon A multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
Information regarding acute overdosage is limited to experience from clinical trials conducted during the development of the CLARINEX product. In a dose ranging trial, at doses of 10 mg and 20 mg/day somnolence was reported.

Single daily doses of 45 mg were given to normal male and female volunteers for 10 days. All ECGs obtained in this study were manually read in a blinded fashion by a cardiologist. In CLARINEX-treated subjects, there was an increase in mean heart rate of 9.2 bpm relative to placebo. The QT interval was corrected for heart rate (QTc) by both the Bazett and Fridericia methods. Using the QTc (Bazett) there was a mean increase of 8.1 msec in CLARINEX-treated subjects relative to placebo. Using QTc (Fridericia) there was a mean increase of 0.4 msec in CLARINEX-treated subjects relative to placebo. No clinically relevant adverse events were reported.

In the event of overdose, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended. Desloratadine and 3-hydroxy-desloratadine are not eliminated by hemodialysis.

Lethality occurred in rats at oral doses of 250 mg/kg or greater (estimated desloratadine and desloratadine metabolite exposures were approximately 120 times the AUC in humans at the recommended daily oral dose). The oral median lethal dose in mice was 353 mg/kg (estimated desloratadine exposures were approximately 290 times the human daily oral dose on a mg/m2 basis). No deaths occurred at oral doses up to 250 mg/kg in monkeys (estimated desloratadine exposures were approximately 810 times the human daily oral dose on a mg/m2 basis).
Kentucky's HIV epidemic displays an especially profound and disproportionate impact among people who inject drugs (PWID): 14.8% of males and 54.2% of females newly diagnosed with HIV in 2021 have an injection drug use-related transmission factor, far exceeding the national average for this exposure category. A central pillar of Ending the HIV Epidemic (EHE) is the prevention of new HIV infections through scale up of Pre-Exposure Prophylaxis (PrEP) in key populations, including PWID. For PWID, PrEP uptake remains severely limited, and no evidence-based PrEP interventions specifically targeted for PWID are available. In the previous pilot in KY's Appalachian region, two brief, low-intensity interventions to promote linkage to co-located PrEP care in rural syringe service programs (SSPs) were successfully implemented, including a newly adapted strengths-based case management (SBCM-PrEP) intervention designed to address multi-level barriers to PrEP initiation. The pilot trial has demonstrated proof of concept for integrated PrEP care within rurally-located SSPs and high acceptability among PWID with high uptake of initial clinical interventions. Nevertheless, just 51% returned for test results, and 28% progressed to PrEP prescription, indicating that augmented intervention support is required to optimize PrEP uptake. The stepped-care Adaptive Interventions (AIs) to be tested respond directly to identified challenges in the pilot trial and the need for augmented support among initial non-responders. AIs have shown remarkable promise in diverse behavioral and medical conditions, including areas such as chronic lower back pain, risky drinking and violent behavior, reducing alcohol use, preventing suicidal behavior, and HIV treatment retention
As the available literature implies that intensive postoperative surveillance has no impact on (cancer-specific) survival outcomes in patients after curative intent surgery for CRC, critical appraisal of the current follow-up practice and guidelines is needed. Although patients in the referenced randomized controlled trials were included roughly 5 - 15 years ago, treatment for recurrent colorectal cancer has seen little to no change since then. Therefore, efforts to improve the current standard of follow-up in patients with CRC should focus on ameliorating quality of life and cost-effectiveness, rather than survival. It provides an opportunity to support patients emotionally, to evaluate treatment effects and complications, and to inform them on their individual prognosis. This is especially true considering the growing importance of value based healthcare and patient reported outcomes in medicine. The investigators therefore propose a patient-led home-based follow-up approach. This follow-up strategy primarily consists of carcinoembryonic antigen (CEA) level monitoring at home, but additional counselling/diagnostic testing remains possible if desired by patients. In this way the investigators hope to meet the individual needs of patients during follow-up and to improve quality of life outcomes, while achieving equal or greater societal cost-effectiveness.
<P>PROBLEM TO BE SOLVED: To provide a taste-concealing microcapsule composition for performing the administration of a medicine.  <P>SOLUTION: This composition consists of the medicine and microcapsules of a substantially water insoluble polymeric material, typically a cellulose-based polymer. The microcapsule composition can be incorporated into a medicinal blend including a chewable tablet, a foaming tablet, powder, liquid dispersion, etc. The method for concealing the taste of the medicine is also provided, and the method requires a relatively high level of a phase separated coacervation technology coated with a polymeric material. These high level coating can perform an effective taste-concealment, and since the medicine is allowed to be released for a desired objective, the medicine is released immediately after passing through mouth.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The present invention provides for the identification and cloning of the RNA component of the telomerase enzyme, human telomerase RNA (telRNA). In another aspect of invention, there is disclosed a novel tumor cell-specific gene therapy, using the telRNA of the invention for the specific destruction of various types of cancers. The human telomerase RNA (telRNA) gene can be identified (isolated) by direct hybridization using an oligonucleotide probe to screen cultured human tumor cells enriched in telRNA (HeLa cells) and/or by PCR/hybrid selection. Once isolated, the gene encoding the telRNA gene is mutated  in vitro  and cloned into a suitable expression vector. The expression vector can be transfected into human cancer cells,  in vitro  or  in vivo . In either case, it is expected that the mutant telRNA will compete with the endogenous telRNA in the formation of active telomerase, resulting in the addition of aberrant telomere sequences to the ends of chromosomes. This is predicted to cause genetic instability and rapid cell death.
NEW MATERIAL:The compound of formulaI(R is ribose residue, arabinose residue, xylose residue, 2-deoxyribose residue, or 3-deoxyribose residue which may habe protective group). EXAMPLE:2-Hydroxy-6-methyl-9-beta-D-ribofuranosyl purine. USE:Adenyldeaminase-inhibiting agent, antitumor agent, antiviral agent, reagent for biochemical research, and antisuntan agent. PROCESS:2-Amino-6-methylpurine nucleoside is subjected to the deamination reaction with nitrous acid, e.g. by reacting with nitrous acid (salt) under acidic conditions at -20 deg.C- room temperature. The starting compound of formula II can be synthesized according to the reaction formula.